Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Starpharma’s VivaGel® Phase 3 trials 60% enrolled

Abstract:
Key points

· Enrolment passes 60% for VivaGel® Phase 3 BV treatment trials

· Trials well on track for completion in 2012

· One of the trials has already enrolled more than 80% of subjects

Starpharma’s VivaGel® Phase 3 trials 60% enrolled

Melbourne, Australia | Posted on June 3rd, 2012

Starpharma Holdings Ltd (ASX:SPL, OTCQX: SPHRY) is pleased to report excellent progress in the recruitment for its pivotal Phase 3 trials for VivaGel® as a treatment for bacterial vaginosis (BV).

Two concurrent Phase 3 trials are underway and recruitment for these trials, which commenced in late March 2012, has recently passed the halfway mark with 60% of patients already enrolled. One of the trials has already exceeded 80% enrolment.

The Phase 3 treatment trials are taking place across more than 30 international sites, primarily in the United States. Following the completion of the Phase 3 trials Starpharma expects to prepare and submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in parallel with engaging in licensing negotiations. The FDA has already provided formal agreement as part of a Special Protocol Assessment (SPA) declaring that the phase 3 trials' design, clinical endpoints and statistical analyses are acceptable for FDA approval once completed.

"We are extremely pleased with the rate of enrolment for the pivotal Phase 3 trials underway. We are already approaching two thirds enrolment in less than three months, which means we are well on track to complete and report the trials in 2012 as indicated," said Dr Jackie Fairley, Chief Executive Officer of Starpharma.

BV is the most common vaginal infection worldwide, and the most common cause of vaginal irritation, discharge and malodour. It is particularly prevalent in the US, where it affects an estimated one-third of the adult female population. BV is often implicated in pelvic inflammatory disease and may also be associated with pre-term birth and an increased risk of sexually transmitted infections, including HIV.

"Completion of these Phase 3 trials is a very important milestone for Starpharma as it is the precursor to seeking regulatory approval for VivaGel® as a treatment for BV," Dr Fairley said.

The market for topical treatments of BV is estimated at US$300-$350 million. However, existing conventional antibiotic treatments are considered suboptimal with relatively low cure rates and high rates of recurrence, unpleasant side-effects, and high levels of bacterial resistance. VivaGel® is a non-antibiotic gel that is applied to the vagina with an applicator. VivaGel® is not absorbed into the bloodstream (as antibiotics are), and as such it is not associated with the side effects of antibiotics. Clinical trials of VivaGel® have shown a high level of patient acceptability.

Details of the Phase 3 trial design are contained in the announcement of the trial commencement made on 22 March 2012 available at www.starpharma.com/asx_announcements

####

For more information, please click here

Contacts:
Haley Price
Account Manager
BUCHAN CONSULTING
LEVEL 13
499 ST KILDA ROAD
MELBOURNE AUSTRALIA 3004
TEL +61 3 8866 1210
MOB +61 (0) 423 139 163
www.buchanwe.com.au

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

University of Akron researchers find thin layers of water can become ice-like at room temperature: Results could lead to an assortment of anti-friction solutions August 30th, 2016

Nanocatalysis for organic chemistry: This research article by Dr. Qien Xu et al. is published in Current Organic Chemistry, Volume 20, Issue 19, 2016 August 30th, 2016

Continuous roll-process technology for transferring and packaging flexible LSI August 29th, 2016

Meteorite impact on a nano scale August 29th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Analog DNA circuit does math in a test tube: DNA computers could one day be programmed to diagnose and treat disease August 25th, 2016

New approach to determining how atoms are arranged in materials August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

New electrical energy storage material shows its power: Nanomaterial combines attributes of both batteries and supercapacitors August 25th, 2016

Nanomedicine

Designing ultrasound tools with Lego-like proteins August 29th, 2016

Nanofiber scaffolds demonstrate new features in the behavior of stem and cancer cells August 25th, 2016

Johns Hopkins scientists track metabolic pathways to find drug combination for pancreatic cancer August 25th, 2016

50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016

Announcements

University of Akron researchers find thin layers of water can become ice-like at room temperature: Results could lead to an assortment of anti-friction solutions August 30th, 2016

Nanocatalysis for organic chemistry: This research article by Dr. Qien Xu et al. is published in Current Organic Chemistry, Volume 20, Issue 19, 2016 August 30th, 2016

Continuous roll-process technology for transferring and packaging flexible LSI August 29th, 2016

Meteorite impact on a nano scale August 29th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic